Pipeline
RSLV-132
Pre Clinical
Phase 1
Phase 2
Phase 3
Post-Viral Diseases
Systemic Lupus
Erythematosus
Sjögren’s Syndrome
Polytrauma
Subarachnoid
Hemorrhage
NETosis
Hidradenitis
suppurativa
RSLV-145
Sjögren’s Syndrome
Patients with Sjögren's syndrome frequently develop autoantibodies to self-antigens, with the most common, anti-Ro, being directed to an RNA-containing antigen. Many patients also have increased expression of interferon regulated genes, which is indicative of the chronic inflammation and neuroinflammation driven by type 1 interferons.
Interferon production is driven by the presence of extracellular RNA across multiple autoimmune diseases, including Sjögren's through binding to RNA sensors such as TLR7. Complicating the situation further, expression of TLR7 is increased in many women with autoimmune disease due to incomplete X chromosome inactivation.
Resolve has pioneered a completely new approach to the treatment of Sjögren's, utilizing RSLV-132 to remove extracellular RNA from circulation to prevent it from activating type I interferons.
Systemic Lupus Erthyematosus
The underlying biology that causes SLE includes a break in self-tolerance and the development of autoantibodies. Numerous autoantibodies have been characterized in lupus patients, including antibodies to double-stranded DNA and RNA-containing autoantibodies. Like Sjögren's syndrome, circulating extracellular RNA triggers the production of type I interferons driving chronic inflammation in these patients, and interferon production is increased due to the presence of pathogenic RNA, and binding to TLR7.
Critical Care
Systemic inflammation is a central feature of patients suffering from critical injuries. Multiple lines of evidence demonstrate that large quantities of extracellular RNA are released into the blood from damaged and dying cells and tissues. This inundation of extracellular RNA leads to an intense burst of inflammation through the activation of RNA sensors, coupled with cytokine production resulting in life-threatening organ damage. On the back of multiple studies supporting the efficacy of RNase treatment to prevent organ damage in animals, Resolve is investigating the use of RSLV-132 as a potential treatment for critical injuries and medical emergencies such as subarachnoid hemorrhage and polytrauma.
.png)